NEEDLE FREE

A peptide synthesized at the Weizmann Institute halts the progression of Type 1 diabetes, also known as Juvenile Diabetes, by reeducating the immune cells to avoid destroying insulin-producing cells.

Israel’s Teva Pharmaceutical and Clal Biotechnology are hopeful that the treatment, which is now in advanced trials, will make insulin injections obsolete for this form of diabetes.